Trial · NCT00771901

Effect of Endoplasmic Reticulum Stress on Metabolic Function

NCT00771901, Not applicable, Completed, Washington University School of Medicine; results first posted 2018-05-29

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effect of Endoplasmic Reticulum Stress on Metabolic Function. Trials, record NCT00771901. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00771901

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effect of Endoplasmic Reticulum Stress on Metabolic Function
NCT number: NCT00771901
Status: Completed
Phases: Not applicable
Enrollment: 101 participants, actual
Lead sponsor: Washington University School of Medicine
Conditions: Insulin Resistance, Diabetes, Obesity
Interventions: tauroursodeoxycholic acid, placebo, sodium phenylbutyrate
First posted: 2008-10-15
Last updated: 2018-05-29
Results first posted: 2018-05-29

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Body Composition	Baseline and four weeks	Fat mass (%)
Secondary	Insulin Sensitivity in the Liver	Baseline and four weeks	HISI (hepatic insulin sensitivity index). HISI is the inverse of the product of endogenous glucose production and plasma insulin concentration and provides an index of how well circulating insulin controls the amount of glucose supplied by the liver. A higher number is indicative of greater insulin sensitivity.
Secondary	VLDL-triglyceride (TG) Concentration	Baseline and four weeks

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Body Composition	Baseline and four weeks	percentage	MEAN
SECONDARY	Insulin Sensitivity in the Liver	Baseline and four weeks	100/ (µmol/min * uIU/mL)	MEAN
SECONDARY	VLDL-triglyceride (TG) Concentration	Baseline and four weeks	mmol/l	MEAN

Source ClinicalTrials.gov

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Body Composition	Placebo	Before Intervention	39	Standard Deviation 7	percentage
Body Composition	Tauroursodeoxycholic Acid	Before Intervention	39	Standard Deviation 8	percentage
Body Composition	Sodium Phenylbutyrate	Before Intervention	37	Standard Deviation 6	percentage
Body Composition	Placebo	After Intervention	39	Standard Deviation 7	percentage
Body Composition	Tauroursodeoxycholic Acid	After Intervention	39	Standard Deviation 8	percentage
Body Composition	Sodium Phenylbutyrate	After Intervention	39	Standard Deviation 7	percentage
Insulin Sensitivity in the Liver	Placebo	Before Intervention	0.010	Standard Deviation 0.007	100/ (µmol/min * uIU/mL)
Insulin Sensitivity in the Liver	Tauroursodeoxycholic Acid	Before Intervention	0.009	Standard Deviation 0.004	100/ (µmol/min * uIU/mL)
Insulin Sensitivity in the Liver	Sodium Phenylbutyrate	Before Intervention	0.008	Standard Deviation 0.003	100/ (µmol/min * uIU/mL)
Insulin Sensitivity in the Liver	Placebo	After Intervention	0.008	Standard Deviation 0.004	100/ (µmol/min * uIU/mL)

1 to 10 of 18Source ClinicalTrials.gov

See all 18 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	10
Overall Study	STARTED	Tauroursodeoxycholic Acid	10
Overall Study	STARTED	Sodium Phenylbutyrate	10
Overall Study	COMPLETED	Placebo	10
Overall Study	COMPLETED	Tauroursodeoxycholic Acid	10
Overall Study	COMPLETED	Sodium Phenylbutyrate	6
Overall Study	NOT COMPLETED	Placebo	0
Overall Study	NOT COMPLETED	Tauroursodeoxycholic Acid	0
Overall Study	NOT COMPLETED	Sodium Phenylbutyrate	4

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals9

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	Placebo	10
Total, all-cause mortality	Tauroursodeoxycholic Acid	10
Total, all-cause mortality	Sodium Phenylbutyrate	6
Total, other adverse events	Placebo	10
Total, other adverse events	Tauroursodeoxycholic Acid	10
Total, other adverse events	Sodium Phenylbutyrate	6
Total, serious adverse events	Placebo	10
Total, serious adverse events	Tauroursodeoxycholic Acid	10
Total, serious adverse events	Sodium Phenylbutyrate	6

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
20522594	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00771901

GET https://conductscience.org/api/trials/v1/NCT00771901/registered

API reference For AI assistants